Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment tags : Als save search
Health Canada Accepts for Review New Drug Submission for Tofersen for Treatment of Rare, Genetic Form of ALS
Published: 2024-03-19 (Crawled : 12:30) - biospace.com/
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -0.33%
H: 1.89%
C: 0.64%
drug health genetic als review treatment canada submission
ALS Treatment Landscape ‘Primed’ with Over 100 Candidates: GlobalData
Published: 2024-03-04 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.8%
H: 0.0%
C: 0.0%
als treatment 100
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M
|
|
| O: 2.33%
H: 1.69%
C: -6.56%
au8 als treatment
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
Published: 2023-12-21 (Crawled : 12:00) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M
|
|
| O: -34.37%
H: 3.49%
C: -6.8%
au8 label als biomarker treatment extension trial platform
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
Published: 2023-11-09 (Crawled : 13:00) - globenewswire.com
KTTA | $7.15 -1.19% 540
|
|
| O: -3.9%
H: 4.05%
C: 4.05%
pas-003 antibody als treatment therapeutics
BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS
Published: 2023-10-18 (Crawled : 10:00) - prnewswire.com
BCLI A | $0.5384 4.69% 4.48% 1M
|
Health Technology
|
| O: 5.0%
H: 0.53%
C: -2.86%
fda als cell nurown treatment therapeutics
Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
Published: 2023-10-13 (Crawled : 00:20) - biospace.com/
AMLX A | $1.88 -5.05% -5.32% 2.5M
|
|
| O: -3.75%
H: 2.83%
C: 2.18%
amx0035 chmp als treatment pharmaceuticals application negative
Coya Therapeutics Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting
Published: 2023-10-05 (Crawled : 15:00) - biospace.com/
COYA | $7.87 -6.75% -7.24% 54K
|
|
| O: 0.0%
H: 13.48%
C: 2.42%
als sclerosis treatment meeting therapeutics
Path for BrainStorm ALS Treatment Remains Rocky, Hope for Others on Horizon
Published: 2023-09-29 (Crawled : 00:20) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
als hope treatment
Path for BrainStorm ALS Treatment Remains Rocky, Hope for Others on the Horiz...
Published: 2023-09-29 (Crawled : 21:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
als hope treatment
BrainStorm Cell Therapeutics Provides Update on FDA Advisory Committee Meeting to Review NurOwn for the Treatment of ALS
Published: 2023-09-28 (Crawled : 03:00) - prnewswire.com
BCLI A | $0.5384 4.69% 4.48% 1M
|
Health Technology
|
| O: -48.44%
H: 6.38%
C: 1.39%
fda als review update cell nurown treatment meeting therapeutics
Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls
Published: 2023-09-25 (Crawled : 11:00) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M
|
|
| O: 4.51%
H: 9.53%
C: -4.11%
cnm-au8 als treatment trial platform
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study
Published: 2023-09-07 (Crawled : 13:00) - prnewswire.com
SNPX | $4.33 -7.08% -7.62% 30K
|
Professional, Scientific, and T...
|
| O: 9.31%
H: 5.47%
C: -19.7%
pre-clinical als treatment results study
Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine
Published: 2023-06-26 (Crawled : 12:00) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M
|
|
| O: 1.9%
H: 3.04%
C: -1.86%
au8 als publication treatment phase 2
Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union
Published: 2023-06-23 (Crawled : 14:00) - biospace.com/
AMLX A | $1.88 -5.05% -5.32% 2.5M
|
|
| O: -1.65%
H: 0.0%
C: -5.38%
amx0035 chmp als treatment pharmaceuticals application negative
Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union
Published: 2023-05-30 (Crawled : 13:00) - biospace.com/
AMLX A | $1.88 -5.05% -5.32% 2.5M
|
|
| O: -4.63%
H: 8.23%
C: 1.52%
amx0035 als review update treatment ongoing pharmaceuticals
FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS
Published: 2023-04-25 (Crawled : 00:00) - prnewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.03%
H: 0.77%
C: -0.39%
fda genetic als treatment
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
Published: 2023-04-25 (Crawled : 20:00) - globenewswire.com
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: 0.03%
H: 0.77%
C: -0.39%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -1.35%
H: 3.82%
C: 3.39%
fda genetic als approval treatment grants
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn® for the Treatment of ALS
Published: 2023-03-27 (Crawled : 11:00) - biospace.com/
BCLI A | $0.5384 4.69% 4.48% 1M
|
Health Technology
|
| O: 16.13%
H: 6.67%
C: -11.11%
nurown fda als license review cell treatment meeting application therapeutics
Clene's Nanocrystal ALS Treatment Bounces Back with Positive Data
Published: 2023-03-09 (Crawled : 18:00) - biospace.com/
CLNN S | $0.3492 5.85% 5.53% 1.2M
|
|
| O: 10.0%
H: 0.7%
C: -5.59%
treatment als back positive
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.